Shumin Liu1,2, Yongfu Wu3, Xu Liu4, Jiahui Zhou1,2, Ziyou Wang1,2, Zhiwei He1,2, Zunnan Huang1,2. 1. a China-America Cancer Research Institute , Guangdong Provincial Key Laboratory of Medical Molecular Diagnostics, Dongguan Scientific Research Center, Guangdong Medical University , Dongguan , China. 2. b Department of Pathophysiology , Guangdong Medical University , Dongguan , China. 3. c Department of Pharmacy , Yuebei People's Hospital , Shaoguan , China. 4. d The Second School of Clinical Medicine , Guangdong Medical University , Dongguan , China.
Abstract
OBJECTIVES: Previous studies have investigated the association between MTHFR A1298C (rs1801131) polymorphism and susceptibility to Alzheimer's disease (AD). Nevertheless, an ultimate conclusion remains obscure. We then executed this meta-analysis to estimate this association more precisely. METHODS: Related studies were systematically searched on PubMed, Embase, China National Knowledge Infrastructure, Google scholar, and AlzGene databases. The association was evaluated by reviewing the odds ratios (ORs) with corresponding 95% confidence intervals (CIs). Publication bias, sensitivity analysis, and cumulative meta-analysis were performed to help draw a more definite conclusion. RESULTS: Ten eligible studies were finally enrolled in this meta-analysis. Lack of association between MTHFR A1298C polymorphism and AD risk was observed in five genetic models (allelic: OR = 1.17, 95% CI: 0.88-1.56; homozygous: OR = 1.15, 95% CI: 0.87-1.53; heterozygous: OR = 1.19, 95% CI: 0.76-1.86; dominant: OR = 1.23, 95% CI: 0.81-1.87; recessive: OR = 1.16, 95% CI: 0.89-1.52). The result of cumulative meta-analysis sorted by publication year was also detected a dynamic tendency of no correlation between MTHFR A1298C polymorphism and AD. CONCLUSION: This meta-analysis reveals that MTHFR A1298C polymorphism may not be associated with AD risk.
OBJECTIVES: Previous studies have investigated the association between MTHFRA1298C (rs1801131) polymorphism and susceptibility to Alzheimer's disease (AD). Nevertheless, an ultimate conclusion remains obscure. We then executed this meta-analysis to estimate this association more precisely. METHODS: Related studies were systematically searched on PubMed, Embase, China National Knowledge Infrastructure, Google scholar, and AlzGene databases. The association was evaluated by reviewing the odds ratios (ORs) with corresponding 95% confidence intervals (CIs). Publication bias, sensitivity analysis, and cumulative meta-analysis were performed to help draw a more definite conclusion. RESULTS: Ten eligible studies were finally enrolled in this meta-analysis. Lack of association between MTHFRA1298C polymorphism and AD risk was observed in five genetic models (allelic: OR = 1.17, 95% CI: 0.88-1.56; homozygous: OR = 1.15, 95% CI: 0.87-1.53; heterozygous: OR = 1.19, 95% CI: 0.76-1.86; dominant: OR = 1.23, 95% CI: 0.81-1.87; recessive: OR = 1.16, 95% CI: 0.89-1.52). The result of cumulative meta-analysis sorted by publication year was also detected a dynamic tendency of no correlation between MTHFRA1298C polymorphism and AD. CONCLUSION: This meta-analysis reveals that MTHFRA1298C polymorphism may not be associated with AD risk.
Authors: Stanislav Sutovsky; Robert Petrovic; Maria Fischerova; Viera Haverlikova; Barbara Ukropcova; Jozef Ukropec; Peter Turcani Journal: J Alzheimers Dis Date: 2020 Impact factor: 4.472